Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07693231
PHASE1

A Study to Test How Well Different Doses of BI 3034701 Are Tolerated by Japanese Healthy People and Japanese People With Obesity or Overweight

Sponsor: Boehringer Ingelheim

View on ClinicalTrials.gov

Summary

Part 1: To investigate safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of BI 3034701 in Japanese male and female participants with body mass index (BMI) ≥27.0 kg/m² or more following subcutaneous administration of multiple rising doses over 16 weeks. Part 2: To investigate safety, tolerability, and PK of BI 3034701 in Japanese male and female healthy participants with BMI ≥23.0 to \<27.0 kg/m² following subcutaneous administration of multiple rising doses over 7 weeks.

Official title: A Phase I, Single-blinded, Randomised, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of BI 3034701 in Japanese Male and Female Participants With Obesity/Overweight and Otherwise Healthy (Part 1) and Safety, Tolerability, and Pharmacokinetics of Multiple Rising Doses of BI 3034701 in Japanese Male and Female Healthy Volunteers (Part 2)

Key Details

Gender

All

Age Range

18 Years - 64 Years

Study Type

INTERVENTIONAL

Enrollment

48

Start Date

2026-07-30

Completion Date

2027-01-29

Last Updated

2026-07-09

Healthy Volunteers

Yes

Conditions

Interventions

DRUG

BI 3034701

BI 3034701

DRUG

Placebo

Placebo

Locations (3)

SOUSEIKAI Hakata Clinic

Fukuoka, Fukuoka, Japan

Fukuoka Mirai Hospital

Fukuoka, Fukuoka, Japan

SOUSEIKAI Sumida Hospital

Tokyo, Sumida-ku, Japan